Finance

JPMorgan Upgrades P&G on Expected H2 Acceleration

JPMorgan analyst Andrea Teixeira upgrades Procter & Gamble to overweight from neutral and lifts the 12-month target to $165. The upgrade follows P&G's Q2 results, with EPS of $1.88 vs. $1.86 expected and revenue of $22.21 billion, shy of the $22.28 billion consensus, as the firm points to a stronger H2 backdrop.

📅 January 23, 2026
⏱️ 2 min read
JPMorgan Upgrades P&G on Expected H2 Acceleration

Key Takeaways

  • JPMorgan raises PG to overweight with a $165 target, implying about 11% upside from the prior close
  • Q2 EPS of $1.88 beat estimates of $1.86; revenue of $22.21B vs. $22.28B consensus
  • OSG is expected to accelerate to 2-3% in 2H from 0% in Q2; US OSG -2%, ex-US OSG +3%
  • Management calls Q2 the trough; 2H growth to come from base effects and potential share recovery
  • Catalysts include corporate restructuring, higher marketing spend, and AI-driven margin improvements; FY2026 earnings unchanged; FY2027-2028 estimates raised; PG down >10% over 12 months

People Involved

  • Andrea TeixeiraJPMorgan analyst

Entities Involved

  • Procter & Gamble (PG)Consumer staples company
  • JPMorgan Chase & Co. (JPM)Investment bank and equity research provider

MarketMoodz Analysis

The upgrade signals a potential re-rating for Procter & Gamble if the 2H acceleration proves durable. With operating margin drivers tied to restructuring, incremental marketing spend, and AI-driven margin improvements, the stock could re-rate on improved cash generation and steadier organic growth. The implied 11% upside adds a tangible path to outperformance relative to peers.

Historically, consumer staples have traded on a mix of reliable cash flow and margin discipline. P&G’s 2H catalysts fit a familiar pattern: troughing in the second quarter, followed by margin expansion as base effects relent and cost measures take hold. A JPMorgan upgrade can prompt related funds to revisit allocations toward durable-goods names, potentially lifting the sector's multiple during a risk-on phase.

What to watch next: monitor Q3 progress on restructuring milestones, marketing spend, and AI ROI impact on margins; track whether 2H organic sales growth meets expectations and if FY2027-2028 estimates sustain their upward revisions. A continued pickup in share count and margin stability would reinforce the bear-case that the stock can extend gains into 2026.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial